Insulin Therapy Center

Apart from Sotagliflozin’s use in the treatment of people with type 2, SGLT-1 and SGLT-2 inhibitors effects on type 1 currently being explored.

In adults with two or more antibodies predicting the development of type 1 diabetes, treatment with daily oral insulin therapy did not prevent development of the disease, but a small subset experienced a 31-month delay in clinical diabetes development.

I have type 1 diabetes and have been living with it for the past 11 years. I take daily insulin injections to stay alive and well. A couple of years ago, I had a very frustrating incident when my insulin stopped working. I began injecting loads of insulin, and even with multiple doses my blood glucose wouldn’t drop.

However, in 2016, Novo Nordisk halted the development of their basal oral insulin tablet.

Results presented in the ADA 77th Scientific Sessions suggests the use of an investigational glucagon-blocking agent can improve glycemic levels and reduce insulin requirements.

The DEVOTE trial compared cardiovascular safety in two basal insulins; insulin degludec was found to have additional benefits.

One long-acting insulin may be better at controlling glycemic variations.

Problems associated with the use of U-500 insulin syringes. We received two reports of accidental prescribing of the new BD U-500 insulin syringes for outpatients who were using a U-100 insulin product. In one case, an endocrinology clinic called the hospital pharmacy to ask how to order U-500 syringes. During the conversation, it became apparent that there was some confusion about the use of these syringes. The pharmacist stressed that the patient should not use a U-500 syringe to measure any insulin concentration other than U-500, or the measurement would be incorrect, leading to a 5-fold underdose.

In this week's Homerun Slides, beta cell failure in type 2 diabetes mellitus and the concept of glucotoxicity.

An endocrinologist prescribed a U-200 TRESIBA (insulin degludec) pen for an 88-year-old woman with labile type 1 diabetes and recurrent hypoglycemia. The patient also has severe macular degeneration with visual impairment. Visually impaired patients commonly use touch and sound to assist them.An endocrinologist prescribed a U-200 TRESIBA (insulin degludec) pen for an 88-year-old woman with labile type 1 diabetes and recurrent hypoglycemia. The patient also has severe macular degeneration with visual impairment. Visually impaired patients commonly use touch and sound to assist them.